These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32627435)

  • 1. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
    Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
    Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
    Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
    Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
    Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
    Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
    PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An atomistic perspective on antibody-dependent cellular cytotoxicity quenching by core-fucosylation of IgG1 Fc N-glycans from enhanced sampling molecular dynamics.
    Harbison A; Fadda E
    Glycobiology; 2020 May; 30(6):407-414. PubMed ID: 31829411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
    Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
    MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
    Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
    Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
    Aoyama M; Tada M; Tatematsu KI; Hashii N; Sezutsu H; Ishii-Watabe A
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2633-2638. PubMed ID: 30119885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
    Branstetter E; Duff RJ; Kuhns S; Padaki R
    FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.
    Pace D; Lewis N; Wu T; Gillespie R; Leiske D; Velayudhan J; Rohrbach A; Connell-Crowley L
    Biotechnol Prog; 2016 Sep; 32(5):1181-1192. PubMed ID: 27160519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies.
    Golay J; Andrea AE; Cattaneo I
    Front Immunol; 2022; 13():929895. PubMed ID: 35844552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating IgG effector function by Fc glycan engineering.
    Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
    Wada R; Matsui M; Kawasaki N
    MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
    Falconer DJ; Subedi GP; Marcella AM; Barb AW
    ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
    Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
    PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.